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Objectives. This study evaluates the concept and diagnostic
efficacy of using serum troponin T for the detection of cardiac
graft rejection.
Background. Cardiac troponin T is a cardiospecific myofibrillar
protein, which is only detectable in the circulation after cardiac
myocyte damage. It might be expected to be released during acute
heart allograft rejection, allowing noninvasive rejection diagnosis.
Methods. In 35 control subjects and in 422 samples from 95
clinically unremarkable heart allograft recipients more than 3
months postoperatively, troponin T serum concentrations were
compared to the histological grade of acute graft rejection in
concurrent endomyocardial biopsies.
Results. Mean troponin T serum concentrations were identical
in control subjects (23.2 6 1.4 ng/liter) and in heart transplant
recipients without graft rejection (International Society for Heart
and Lung Transplantation [ISHLT] grade 0; 22.4 6 1.7 ng/liter).
Mean troponin T concentrations increased in parallel with the
severity of graft rejection (ISHLT grade 1: 27.8 6 1.8 ng/liter;
grade 2: 33.2 6 2.7 ng/liter; grade 3A: 54.6 6 6.5 ng/liter; grade 3B
and 4: 105.4 6 53.7 ng/liter; p < 0.001 for grades 3 and 4 vs.
grades 0 and 1). The proportion of positive samples also increased
in parallel with rejection severity, reaching 100% in rejections of
grade 3B and 4. Sensitivity and specificity for the detection of
significant graft rejection (ISHLT grade 3/4) were 80.4% and
61.8%, respectively. The negative predictive value was most re-
markable with 96.2%. Intraindividual longitudinal analysis of
troponin T levels and biopsy results in 15 patients during long-
term follow-up confirmed these findings.
Conclusions. The present data demonstrate that acute allograft
rejection after human heart transplantation is often associated
with increased serum concentrations of troponin T. All cases of
serious forms of graft rejection would have been detected before
the development of clinical symptoms. Measurement of troponin
T levels may become a useful ancillary parameter for noninvasive
rejection diagnosis, being most valuable in the exclusion of severe
cardiac graft rejection.
(J Am Coll Cardiol 1998;32:405–12)
©1998 by the American College of Cardiology
The cardiac myofibrillar protein troponin T has several poten-
tial advantages in the diagnosis of myocardial cell damage over
the measurement of more traditional serological markers such
as lactate dehydrogenase (LDH) or creatine kinase (CK).
These include its expression as a strictly cardiospecific isoform,
the high intracellular concentration and rapid release upon cell
damage (1–4). A specific enzyme immunoassay is available for
the determination of circulating cardiac troponin T, showing
very little cross-reactivity with troponin T isoforms from skel-
etal muscle (3,5). With current commercial immunoassays,
circulating cardiac troponin T is only detectable in the pres-
ence of cardiac muscle damage as in severe cases of unstable
angina, myocardial infarction or after cardiac surgery (4,6,7).
Recently, we and others described continued release of
cardiac troponin T over 2 to 3 months after heart transplan-
tation (1,2,8), outlasting troponin T release following myocar-
dial infarction or standard cardiac surgery, the exact cause
being still unclear. In some cases, episodes of early postoper-
ative rejection seemed to be accompanied by slight rises in
troponin T serum levels, overshadowed mainly, however, by
the high troponin T background concentrations (8).
Acute allograft rejection after heart transplantation is char-
acterized by immune-mediated myocardial cell destruction; it
therefore appears conceivable that rejection episodes should
lead to elevated serum troponin T concentrations through
release from damaged cells, detectable mainly after cessation
of the early posttransplant release described above. Prelimi-
nary experimental animal data by Walpoth et al. (9) and
ourselves (unpublished data) suggest such an increase in serum
troponin T levels in severe rejection. Despite continuing efforts
in serology and with alternative methods (magnetic resonance
imaging [MRI] [10], signal-averaged electrocardiogram [ECG]
[11], specialized echocardiographic indices [12,13], cytoimmu-
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nological monitoring [14]), there are currently no reliable and
easily available parameters for routine noninvasive rejection
monitoring after heart transplantation.
Classic markers of myocyte injury like CK and its MB
isoform were found not to be sufficiently sensitive (15–17).
Therefore, a sensitive cardiospecific marker indicating myocyte
damage due to allograft rejection could be a useful adjunct in
noninvasive rejection diagnosis after cardiac transplantation.
The present study evaluates the use of serum troponin T
measurements with optimized sensitivity for the detection of
ongoing acute allograft rejection in humans.
Patients and Methods
Controls. The control group comprised 35 healthy blood
donors (20 male, 15 female, mean age: 35.4 6 15.2 years,
range: 19–52).
Heart transplant patients. Ninety-five heart transplant re-
cipients were studied; clinical data are shown in Table 1. Only
patients beyond 3 months after operation were included in the
study. Patients gave written consent, and the study was ap-
proved by the local institutional ethics committee. Exclusion
criteria were signs of graft failure (clinical examination, routine
echocardiography, electrocardiogram, hemodynamic compro-
mise), severe transplant atherosclerosis with significant lesions
on coronary angiograms, renal failure (serum creatinine con-
centration .4 mg/dl) or cytomegalovirus infection involving
the myocardium (evidenced by positive immunostaining). Pa-
tients were treated with standard triple drug immunosuppres-
sion with cyclosporine A, corticosteroids and azathioprine,
azathioprine being withheld with blood leukocyte counts below
4000/mm3 (4/nl); details of immunosuppression are shown in
Table 1. In all patients, endomyocardial biopsy results and
serum samples were available concurrently. Biopsy material
was obtained as part of routine posttransplant care; endomyo-
cardial biopsies were performed at routine intervals; histolog-
ical rejection diagnosis was graded according to the nomen-
clature by the International Society of Heart and Lung
Transplantation (ISHLT) of 1990 (18). As the study was
performed in the years 1992 to 1995, the diagnosis of ISHLT
grade 2 rejection was included in biopsy evaluation and data
analysis. In all cases of cellular infiltration compatible with a
diagnosis of rejection $ ISHLT grade 2 immunostaining for
cytomegalovirus antigen pp65 was performed (anti-CMV an-
tibody E-13, Paesel und Lorei, Frankfurt, Germany) to exclude
cytomegalovirus myocarditis. Acute rejection episodes were
treated with 3 3 1 g of intravenous methylprednisolone or 6 3
100 mg of oral methylprednisolone, based on clinical decision;
1 patient required an additional 3-day course of antithymocyte
globulin (5 mg/kg body weight per day) for steroid refractory
rejection (ISHLT grade 4). No patient included in the study
received methotrexate, OKT-3 or FK506.
Troponin T concentrations were measured in available
serum samples from all cases of serious acute graft rejection
(ISHLT grades $2) between June 1992 and June 1995 (n 5
144) and in 271 samples of patients with no or only mild
allograft rejection, matched for similar time after transplanta-
tion. In the study period, 7 cases of severe, stenosing immune
vasculitis without myocardial cellular infiltrates were noted.
These could not be graded by ISHLT nomenclature, but they
were clinically regarded as significant rejection, treated accord-
ingly and included in the study for troponin T determination as
a separate group.
Longitudinal analysis. In 15 long-transplanted patients (13
male, 2 female, age: 49.5 6 27.1 years [range: 24–63], preop-
erative diagnoses: dilated cardiomyopathy: n 5 9, ischemic
heart disease: n 5 6) an intraindividual longitudinal analysis
comparing serial serum troponin T measurements with histo-
logical rejection grades was performed. The mean length of
postoperative study was 695 6 672 days (range: 370–1213)
with a total of 23 rejection episodes (ISHLT grade $3, median
per patient 5 1, range 0–2). One hundred sixty-eight biopsies
and troponin serum levels were evaluated (median per patient:
10, range 5–20).
Enzyme-linked immunosorbent assay (ELISA). Troponin
T concentrations were measured in an optimized one-step
Abbreviations and Acronyms
CK 5 creatine kinase
ECG 5 electrocardiogram
ELISA 5 enzyme-linked immunosorbent assay
ISHLT 5 International Society for Heart and Lung Transplantation
LDH 5 lactate dehydrogenase
MRI 5 magnetic resonance imaging
Table 1. Heart Transplant Recipients: Demographic and
Clinical Data
Male/female (n) 78/17
Number of biopsies/serum samples per patient
(n [median (range)])
4 (1–7)
Age (years [mean (SD), range]) 48.2 (11.4), 18–63
Time after transplantation* (days [median (range)]
All 470 (93–2100)
Grade 0† 518 (93–1935)
Grade 1 388 (94–2100)
Grade 2 501 (96–1998)
Grade 3A 360 (95–2085)
Grade 3B/4 176 (120–501)
Preoperative diagnosis (n)
Dilated cardiomyopathy 60
Ischemic heart disease 30
Other 5
Cyclosporine blood level (mg/liter [weighted
mean 6 SD (range)]
237 6 74 (160–324)
Daily steroid dose (mg [mean 6 SD (range)]
First postoperative year (n 5 95) 14.8 6 5.3 (5–30)
.1 year postoperative (n 5 81) 7.3 6 2.4 (3.5–10)
Daily azathioprine dose (n 5 67) (mg [mean 6
SD, (range)]
59.4 6 44 (25–150)
*Mean time after transplantation refers to all 422 serum samples/
endomyocardial biopsies. †Nomenclature of the International Society of Heart
and Lung Transplantation for rejection severity.
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ELISA based on the Enzymun-Test Troponin T (Boehringer
Mannheim, Mannheim, Germany). A biotinylated troponin T
antibody (1B10) was precoated to a streptavidin-covered mi-
crotiter well plate. Fifty microliters of sample were added with
200 ml of a second cardiospecific troponin T antibody (M7)
covalently linked to peroxidase in incubation buffer (0.1 mol/
liter sodium citrate, 0.47 mol/liter Na2HPO4, 0.1% bovine
serum albumin at pH 6.3). After 40 min incubation, plates were
washed three times, then 250 ml of ATBS (Boehringer Mann-
heim, Mannheim, Germany) substrate were added. After
60 min incubation, microtiter plates were read at 405 nm on an
microtiter reader photometer (SLT, Crailsheim, Germany).
For quantitation, linear standard curves were established over
the required concentration range using bovine troponin T
standards supplied by the manufacturers.
Data analysis. For comparison of continuous data, tropo-
nin T determinations below the detection limit were assigned
the concentration of the detection limit (15 ng/liter) in order to
rather underestimate differences between groups. In addition,
the proportion of positive troponin T determinations was
compared between patient groups using the detection limit (15
ng/ml) as cutoff level for positive versus negative troponin T
determinations. Differences between patient groups were eval-
uated by analysis of variance, followed by the Bonferroni t test
or chi-square test as applicable. Comparison of serum troponin
T with clinical and laboratory variables was done by linear
regression analysis or U test. Statistical significance was as-
sumed for p , 0.05; data analysis was performed using the SAS
statistical software package.
Results
ELISA. The ELISA used for this study was optimized for
greater sensitivity compared to currently available commercial
assays by sequential step performance in streptavidin-coated
microtiter plates and longer incubation times. The detection
limit was experimentally determined according to Kaiser (19);
photometric absorption of blank values (n 5 12) was 0.161 6
0.0032 (mean 6 1 SD), with 17 ng/liter of troponin T (n 5 12)
absorption was 0.184 6 0.0042. Extrapolating from the gradi-
ent of the troponin T standard curve, the detection limit was
determined at 15 ng/liter. The intraassay and interassay coef-
ficients of variation were 2.3% and 6.4%, respectively.
Control subjects. In the control subjects, mean troponin T
concentrations were 23.2 6 1.4 ng/ml (Fig. 1); the proportion
of positive troponin T tests in the control subjects was 25.7%
(Fig. 2).
Cardiac troponin T levels in heart transplant patients.
Troponin T serum levels were measured in 422 blood samples
of 95 heart transplant recipients, including all cases of more
severe allograft rejection (ISHLT grades $3). The distribution
of rejection grades and timepoints of determination is shown in
Table 1 and Figure 1. The temporal relation of the different
rejection grades to transplantation was similar in all groups;
only very severe graft rejections (ISHLT grade 3B and 4)
occurred earlier after transplantation (Table 1). Based on the
exclusion criteria of the study, all transplant patients had
normal graft function on routine echocardiography. Cases of
confirmed or potential cytomegalovirus infection of the myo-
cardium by immunohistology (n 5 2) were not included in the
analysis.
In patients without graft rejection (ISHLT grade 0), mean
serum concentrations of troponin T were identical to control
levels (22.4 6 1.7 ng/liter vs. 23.2 6 1.4 ng/liter, p 5 NS; Fig.
1). In transplant patients with graft rejection, mean troponin T
concentrations increased in parallel with the severity of graft
rejection (mean 6 SEM; ISHLT grade 1: 27.8 6 1.8 ng/liter;
grade 2: 33.2 6 2.7 ng/ml; grade 3A: 54.6 6 6.5 ng/liter; grade
3B and 4: 105.4 6 53.7 ng/liter; Fig. 1). The highest troponin T
level occurred in the only case of grade 4 rejection (318 ng/ml).
For ISHLT grades 3 and 4, the differences were statistically
significant versus controls and ISHLT rejection grades 0/1 (p ,
0.001) and also versus ISHLT grade 2 (p , 0.05). Troponin T
Figure 1. Mean troponin T serum concentrations
(6SEM [ng/liter]) in separate groups of ISHLT rejection
grade versus controls *Significant differences (p , 0.001)
versus controls and ISHLT grade 0/1 rejection.
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levels in grade 1 and 2 rejection were not significantly different
from controls (Fig. 1).
Using the detection limit of the assay at 15 ng/liter as a
diagnostic cutoff level, the proportion of positive samples
(above cutoff) also increased in parallel with rejection severity,
reaching 78% in grade 3A rejection and 100% in grade 3B and
4 rejection (32/41 and 5/5 cases, respectively; Fig. 2). The
proportion of positive samples in cases of rejection with
ISHLT grade 3A and 3B/4 was significantly higher than in
cases of no or mild rejection (ISHLT 0–1; p , 0.001; Fig. 2).
With grade 2 rejection, the proportion of positive samples was
also higher than in cases of no or mild rejection, but on a much
lower level of significance (p , 0.02). Again there was no
significant difference between control subjects and patients
with no or mild rejection (25.7% vs. 27.2% and 36.9%, p 5
NS).
Comparison of all cases of more severe forms of rejection
(ISHLT grades 3 and 4) with lower rejection grades (ISHLT
grades 0–2) showed significantly higher mean troponin T
serum levels in serious rejection with 60.1 6 8.5 ng/liter versus
27.6 6 2.0 ng/liter, p , 0.001. The proportion of positive
troponin T determinations was also significantly higher in
severe forms of rejection (80.4% vs. 38.2%, p , 0.001). From
these data, sensitivity and specificity of troponin T determina-
tions for the detection of serious rejection (ISHLT grades 3
and 4) were determined at 80.4% and 61.8%, respectively. The
negative predictive value of the troponin T test was 96.2%
(absence of a serious form of allograft rejection with troponin
T concentration below the diagnostic cutoff).
During the study period there were 7 cases of severe
stenosing immune vasculitis without any myocardial cellular
rejection (isolated vasculitic rejection) and qualitatively unim-
paired left ventricular function. Mean troponin T serum con-
centrations of these cases were significantly increased versus
control levels or levels in cases with rejection of ISHLT grade
0 or 1 (42.9 6 9.0 ng/liter; p , 0.01). In all 7 cases the serum
troponin T levels were above the diagnostic cutoff (100%).
Troponin T levels were not correlated with the time after
transplantation, either in an overall analysis (r 5 20.053, p 5
NS) or when limited to severe cases of graft rejection (ISHLT
3 and 4; r 5 20.104, p 5 NS). Troponin T serum concentra-
tions were not significantly correlated with any other clinical or
laboratory variables. There were no cases of severe systemic
infections among the study patients; minor flu-like illnesses
and bacterial pneumonia (n 5 3) in the absence of allograft
rejection did not affect troponin T serum concentrations (not
shown). Serum creatinine concentrations as a marker of renal
excretory function were not correlated with troponin T con-
centrations (r 5 0.078, p 5 NS); also recipient or donor age,
gender and liver function parameters showed no association.
In all serum samples, CK serum concentrations were deter-
mined in parallel; in only 8 cases CK levels above the upper
limit of normal (80 U/liter) were detected ranging from
85U/liter to 224U/liter without any correlation to allograft
rejection. Overall, CK serum concentrations were not signifi-
cantly different between cases of severe rejection (ISHLT
grade 3 1 4) and those of no or mild forms of rejection
(ISHLT 0–2) with 33.2 U/liter versus 31.4 U/liter (p 5 NS). No
association of CK levels with rejection severity or troponin T
levels could be demonstrated. CK-MB isoforms were not
investigated.
Longitudinal studies. In 15 long-term transplant patients
an intraindividual longitudinal analysis was performed retro-
spectively on 168 biopsies and corresponding serum samples
for troponin T determination. Due to the doubtful significance
of ISHLT grade 2 rejections (n 5 4, troponin T elevation in
2/4), these were excluded from this analysis. Twenty-three
episodes of advanced rejection (ISHLT grade $3) were diag-
nosed within the study period; 34 samples with elevated
troponin T concentrations were identified. A summary of the
results of the longitudinal comparison of troponin T levels and
histological rejection grades is presented in Table 2.
In 21 of 23 episodes (91.3%) of significant acute graft
rejection a concordant rise of troponin T serum concentrations
Figure 2. Proportion of positive troponin T determina-
tions (levels above cutoff at 15 ng/ml) in separate groups
of rejection grade and controls. *Significant difference
versus controls and ISHLT grade 0/1 rejection: p ,
0.001; # 5 ditto, with p , 0.02.
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with rejection and subsequent decline during recovery (usually
by increased antirejection therapy) was found. A concordant
course of troponin T levels was assumed if, after a rejection-
free period with stable troponin T levels below the detection
limit, troponin T concentrations rose above the detection limit
during a rejection episode and returned to prerejection levels
with or soon after histological recovery. In the remaining 2
cases (8.7%), rejection episodes (ISHLT grade 3A) occurred
without definite increases in troponin T concentrations (false
negatives); both these incidents occurred very late after trans-
plantation (45 and 100 months). In 13 of 34 cases (38.2%) with
increases in troponin T serum levels no concomitant histolog-
ical evidence of graft rejection was found (false positives); in
128 of 145 cases without significant rejection (88.3%) no
significant rise in troponin T was detectable (true negatives).
On the basis of these data, sensitivity and specificity of the
longitudinal troponin T analysis were calculated at 91.3% and
88.3%, the negative predictive value being .98%. In 2 addi-
tional patients, there was unexplained, continued release of
troponin T without evident clinical symptoms. Figure 3 shows
2 examples of concordant behavior of troponin T levels and
rejection severity, among them the only case (EP) of ISHLT
grade 4 rejection requiring therapy with antithymocyte globu-
lin displaying markedly elevated troponin T levels.
Discussion
In contrast to liver or kidney transplantation, there is
currently no established serologic marker for noninvasive
diagnosis of allograft rejection after human heart transplanta-
tion. Experimental noninvasive methods such as MRI (10),
signal averaged ECG (11), specialized echocardiographic in-
dices (12,13) or cytoimmunological monitoring (14) have been
described; apart from being more technically demanding, less
readily available and very costly, they currently do not offer
sufficient diagnostic reliability, especially at later stages (.3
months) after heart transplantation.
Troponin T levels in graft rejection: cross-sectional analy-
sis. The present study demonstrates that acute cellular graft
rejections occurring more than 3 months postoperatively are
often associated with increased serum concentrations of the
cardiospecific isoform of the myofibrillar protein troponin T.
Troponin T serum levels and the proportion of samples above
the diagnostic cutoff level rise in parallel with rejection severity
(Fig. 1 and 2). Using the current detection limit of the assay (15
ng/liter) as the cutoff level, all cases of the most serious forms
of allograft rejection (ISHLT grades 3B and 4) would have
been detected at a presymptomatic stage. Based on the results
of the cross-sectional analysis, the sensitivity and specificity of
positive troponin T determinations for significant rejection
(ISHLT grade 3/4) were 80.4% and 61.8%, respectively. More
remarkable was, however, a negative predictive value of tro-
ponin T testing of 96.2%, suggesting that in the absence of
detectable serum levels of troponin T significant allograft
rejection is highly unlikely. An intraindividual longitudinal
analysis of 15 patients during long-term follow-up confirmed
these findings with further improved sensitivity and specificity
(91.3% and 88.3%). In 7 additional cases elevated troponin T
levels were found in severe immune vasculitis without myocar-
dial involvement.
Pathomechanism. It appears most likely that this release of
myocardial troponin T should originate from cardiac myocytes
injured during the rejection process; a continuous release of
troponin T over the first 2 to 3 months after heart transplan-
tation has been described by our group (8). In experimental rat
heart transplantation increased troponin T serum levels could
be demonstrated in advanced graft rejection ([9] and our own
unpublished observation), but the sensitivity of troponin T
determination was limited by postsurgical troponin T release.
Hossein et al. suggested the potential use of troponin T for
noninvasive diagnosis of graft rejection (20). This study in-
cluded only 6 patients, and the reported absence of elevated
troponin T levels at the time of ongoing histological rejection
is difficult to interpret. Wang et al. recently reported on the
inability of myocyte death markers to predict cardiac allograft
rejection (21); troponin T levels in rejectors were, however,
indeed higher than in nonrejectors, though not statistically
significantly. The present study thus appears to be the first
demonstration of a consistent rise in the serum concentration
of a cardiospecific marker during serious allograft rejection in
a large series of patients after human heart transplantation.
In the cross-sectional and longitudinal analysis all cases of
ISHLT grade 3B and 4 rejection would have been detected by
troponin T testing before clinical signs of graft failure oc-
curred. It is important to realize that according to a data
analysis of the Cardiac Transplant Research Database only 3%
of ISHLT grade 3B rejections and 8% of grade 4 rejections
were associated initially with hemodynamic compromise or
other clinical signs (22). Noninvasive monitoring by troponin T
testing could be particularly valuable for the detection of
allograft rejection at a stage beyond routine performance of
endomyocardial biopsies.
Troponin T negative graft rejection. In a noninvasive
screening test such as described here, false negative results are
generally considered the most critical incidents, as true pathol-
ogy is being missed. In the cross-sectional analysis of troponin
Table 2. Square Table Analysis of Retrospective Intraindividual
Longitudinal Comparison of Troponin T Serum Concentrations
Measured by ELISA and Histological Rejection Grades in














Total 34 130 164
Median number of biopsies per patient: 10 (range: 5–20), mean length of
follow-up: 695 days (range: 370–1213).
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T levels, 19.6% of more serious forms of allograft rejection
(ISHLT grades 3 and 4) were not accompanied by a detectable
increase in troponin T serum concentrations; all these inci-
dents were limited to the lowest rejection grade within this
subgroup, ISHLT 3A. In the intraindividual longitudinal anal-
ysis, this proportion was considerably improved, decreasing to
only 2 of 23 cases (8.7%). As all these patients were clinically
unremarkable at the time of rejection diagnosis, these inci-
dents could represent early and still relatively mild rejection
episodes, which might have become troponin T positive at a
later stage. Troponin T negative forms of rejection might also
be explained by the fact that myocardial cell damage during
graft rejection occurs over a much more protracted period of
time as compared, for example, to myocardial infarction or
cardiac surgery. In contrast to animal experiments, the per-
centage of damaged myocardium in clinical graft rejection is
usually much smaller due to concurrent immunosuppression,
limiting the release of troponin T. Thus, due to the short serum
half-life of troponin T (10 min), significant serum concentra-
tions may fail to develop, particularly in slowly progressing
rejection episodes.
Elevated troponin T levels without rejection. The de-
scribed troponin T test displays a comparatively high frequency
of positive troponin T determinations, seemingly in the ab-
sence of underlying pathology (rejection, gross graft vascular
disease, ischemic heart disease). This proportion of apparently
false positive results reaches 25% already in the healthy
control subjects and is not significantly increased in transplant
patients showing no or only mild forms of rejection. Increasing
the cutoff level did not significantly improve the specificity of
the test, and it increases the risk of falsely negative results.
False positive troponin T tests might be caused by undetected
Figure 3. Longitudinal intraindividual analysis of tropo-
nin T concentrations (cTNT) and biopsy results. A,
Patient EP, male, 48 years old. B, Patient WW, male, 42
years old. Tx, antirejection therapy.
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ischemic events, for example, on the basis of transplant ath-
erosclerosis, undetected ischemic heart disease (in the control
subjects), intercurrent disease or other unknown factors. In
fact, there was a trend for elevated troponin T levels without
histological rejection to occur at later stages after transplanta-
tion in the longitudinal study, highlighting the potential influ-
ence of undetected graft vascular disease. The elevated tropo-
nin T concentrations in the cases of isolated stenosing immune
vasculitis also underline the impact of microvascular lesions on
troponin T release.
ISHLT grade 2 rejection. The data of this study may also
contribute to the ongoing debate on the significance of ISHLT
grade 2 rejection (23). Absolute troponin T levels are slightly,
but not significantly, higher in grade 2 rejection than with no or
grade 1 rejection. Thus, ISHLT grade 2 rejection might be
considered a milder form of rejection similar to grades 0 and 1,
not requiring therapy. The complex role of grade 2 rejection is,
however, further illustrated by the 50% proportion of troponin
T positive samples in cases of grade 2 rejection, which might
warrant viewing grade 2 rejection as a separate intermediate
form (p , 0.02 vs. ISHLT 1 and ISHLT 3A).
Longitudinal analysis. Sensitivity and specificity of tropo-
nin T testing were improved with intraindividual longitudinal
analysis of samples. This may be accounted for by the selection
of patients that had experienced several rejection episodes,
therefore the biological severity (and the propensity for detect-
able troponin T release) may have been greater in these
patients than in the cross-sectional analysis, despite the same
histological diagnosis of ISHLT grade 3A rejection. Further-
more, continuous longitudinal monitoring allows the detection
of a rejection episode at a somewhat later, but still clinically
unremarkable, stage. Also, patients with constantly elevated
troponin T levels, which can only be excluded in longitudinal
monitoring, will increase the frequency of false positive results
in cross-sectional studies.
Correlation with other clinical data. Apart from rejection
severity, troponin T levels were not associated with any other
clinical or laboratory parameters. Especially, no association
with serum concentrations of the classic marker of myocyte
damage, creatine kinase and its MB isoform, could be demon-
strated, confirming previous findings (15–17). While no severe
systemic infections were present among the study patients,
minor infections and bacterial pneumonia in 3 cases did not
affect troponin T concentrations in the absence of allograft
rejection. The relatively large number of severe rejections at a
later postoperative stage explains the lack of an inverse
correlation of troponin T levels and time after transplantation.
Troponin T release during some of these late rejections was
similar to early postoperative rejections, suggesting that com-
parable myocardial injury can occur. Although an effect of
impaired renal function on troponin T elimination has been
demonstrated (5), renal function was not shown to influence
troponin T serum concentrations in this study; however, pa-
tients with manifest renal failure (creatinine .4 mg/dl) had
been excluded. Age, gender and preoperative diagnosis also
had no effect upon troponin T levels.
Methodology/availability. In the present study an opti-
mized troponin T ELISA was used with markedly improved
sensitivity over currently available commercial assays (approx-
imate factor 6–10). Current commercial assays use a diagnostic
cutoff at 0.1 to 0.15 ng/ml (100–150 ng/liter). Only 13 of 185
positive samples (7%) in this study displayed concentrations
above 100 ng/liter; a large proportion of positive samples
would therefore have remained undetected by available com-
mercial assays. In view of the proportion of positive samples
among healthy controls (25.7%), a further increase in sensitiv-
ity appears unlikely to add to the diagnostic efficiency of
troponin T testing.
The modified, noncommercial version of the troponin T
used in this study is based on the Trop T-Enzymun test
(Boehringer Mannheim, Mannheim, Germany). The necessary
reagents can, however, be taken directly out of the commercial
ELISA kit, and the necessary changes in the test protocol will
easily be adopted by any clinical laboratory. The cost of a single
troponin T determination currently comes to approximately
$10–20 per test.
Limitations. Limitations of the present study include the
retrospective analysis and the overrepresentation of higher
grade rejections by design, but the large number of samples
and patients allow valid statistics. Use of the detection limit as
cutoff level was taken into consideration by choosing a statis-
tical approach underestimating differences between patient
groups. Due to the retrospective approach and troponin T
determinations only at the timepoint of endomyocardial bi-
opsy, the course of troponin T concentrations in the period
leading up to rejection cannot be evaluated. On theoretical
grounds, however, the development of elevated troponin T
levels during the induction phase of allograft rejection without
myocardial cell damage appears less likely.
Future studies. To further assess the diagnostic efficacy of
troponin T testing and confirm the present results more
longitudinal data in individual patients will be required, ideally
in a prospective and multi-institutional setting. Analysis of
possible management decisions based on troponin T results
will allow the quantitation of reductions in required biopsies
and health care costs. The role of graft atherosclerosis on
troponin T serum levels and potential diagnostic consequences
will require further investigation. Troponin T levels in humoral
rejection and the potential confounding influence of cytomeg-
alovirus myocarditis cannot be addressed on the basis of the
present data, since they were excluded from analysis. Also, the
clinical significance of patients exhibiting continually elevated
troponin T levels after transplantation needs to be elucidated
further.
Conclusions and clinical implications. In summary, these
data demonstrate that cardiac allograft rejection is often
associated with increased serum concentrations of cardiac
troponin T in a very sensitive assay, proving the feasibility of
detecting cardiac graft rejection by an elevation of cardiospe-
cific serological markers. All cases of the more severe forms of
acute graft rejection would have been detected by troponin T
determination before the occurrence of clinical symptoms.
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Most remarkable, however, is the negative predictive value of
troponin T testing of over 95%, supporting the assumption that
in the absence of detectable serum troponin T levels the
allograft is stable and significant rejection unlikely. Consider-
ing the confounding factors in the interpretation of troponin T
test results, it becomes clear that this diagnostic method will
not be applicable for every patient and that continuous longi-
tudinal monitoring of troponin T levels will prove most reliable
for diagnostic purposes. Even then, troponin T determination
may not be suitable as a single noninvasive parameter for the
diagnosis of graft rejection after heart transplantation. An
important role of troponin T testing as an ancillary method for
the exclusion of serious graft rejection during routine
follow-up could, however, be envisaged, especially as potential
alternative diagnostic modalities (MRI, specialized echocar-
diographic indexes, signal-averaged ECG, cytoimmunological
monitoring) are considerably more technically demanding,
costly and currently not widely available.
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